Numinus is a startup Canadian psychedelic science research company focused on naturally occurring magic mushroom compounds for treating a variety of health conditions. The company was founded by Payton Nyquvest and Stacey Wallin.
- Numinus Bioscience – This is Numinus’s testing and research facility. Their goal is to “leverage the emerging market of psychedelic-assisted psychotherapies to address mental illness, addictions, and PTSD.”
- Numinus Health – “Numinus Health will provide places for psychedelic therapies to take place in a safe, controlled, therapeutic environment.” This treatment center model is planning to scale its services globally.
- Numinus Research & Development – The R&D division is “creating partnerships with leading research groups to advance practice and understanding in the space.”
On October 24th, 2020, Numinus announced that it has successfully cultivated magic mushrooms under a Health Canada-issued Controlled Drugs and Substances Dealer’s Licence. Numinus says in a press release on their website that they have “…received Health Canada approval to amend the Company’s existing license under the Controlled Drug and Substances Act to allow Numinus researchers to conduct research to standardize the extraction of psilocybin from mushrooms.”
According to an article in Forbes, this is the first time a Canadian company has legally cultivated and harvested psychedelic mushrooms since the 1970s. The license also gives Numinus the right to sell Psilocybe mushroom fruiting bodies and extracts from them for clinical research protocols and develop standardized testing for additional psychedelic substances.
While there is a place for synthetic psilocybin in clinical practice, well-characterized and standardized extracts of natural forms of psilocybin cultivated and processed under stringent quality control protocols, are the wave of the future as therapeutic psilocybin gains acceptance.
According to their LinkedIn profile, Numinus plans on building a “purpose-built facility” in Vancouver in 2021.